Related Experiment Video
Updated: Jul 9, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease
Feng-Shiun Shie1, Randall L Woltjer
1Division of Mental Health and Substance Abuse, National Health Research Institutes, No.35 Keyan Road, Zhunan Town, Miaoli County 350, ROC, Taiwan. fshie@nhri.org.tw
Abstract:
Alzheimer's disease (AD) is the leading cause of dementia. Although the etiology of AD remains controversial, the amyloid hypothesis suggests that beta-amyloid (Abeta) peptides may contribute to brain dysfunction, and microglial activation has become increasingly regarded as a potential contributor to disease pathogenesis. Microglial activation is characterized by morphological changes and by production of various effectors, and activated neuroinflammation concurrent with increased oxidative stress may contribute to damage to neurons. However, recently there has been a recognition that microglia may also play a neuroprotective role through their release of neurotrophic factors and through phagocytosis of Abeta. Thus, there is growing consensus that a favorable combination of diminished microglia-mediated neuroinflammation and enhanced Abeta clearance may be critical in AD therapy. In this review, we will discuss the role of microglial activation in AD and how pharmacologic manipulation of microglia might bear upon the treatment of AD.
Insights
Microglial activation in Alzheimer's disease (AD) presents a dual role, potentially causing neuroinflammation or offering neuroprotection. Targeting microglia may offer a novel therapeutic strategy for AD by modulating neuroinflammation and enhancing amyloid-beta clearance.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Alzheimer's disease (AD) is the primary cause of dementia, with its etiology debated.
- The amyloid hypothesis implicates beta-amyloid (Abeta) peptides in AD pathogenesis.
- Microglial activation is increasingly recognized as a key factor in AD development.
Purpose of the Study:
- To review the multifaceted role of microglial activation in Alzheimer's disease.
- To explore the potential of pharmacologic manipulation of microglia for AD treatment.
Main Methods:
- Literature review of studies on microglial activation in AD.
- Analysis of the dual neuroinflammatory and neuroprotective functions of microglia.
- Examination of therapeutic strategies targeting microglial pathways.
Main Results:
- Microglial activation involves morphological changes and effector production, potentially leading to neuroinflammation and oxidative stress.
- Activated microglia can also exert neuroprotective effects via neurotrophic factors and Abeta phagocytosis.
- A balance between reduced neuroinflammation and enhanced Abeta clearance by microglia is crucial for AD therapy.
Conclusions:
- Microglial activation plays a complex role in Alzheimer's disease pathogenesis.
- Pharmacologic modulation of microglial activity represents a promising therapeutic avenue for AD.
- Future AD treatments may focus on optimizing microglial functions for both reduced inflammation and improved Abeta clearance.
